Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group increased its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 415.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 407,215 shares of the company’s stock after purchasing an additional 328,204 shares during the quarter. Schroder Investment Management Group’s holdings in Dr. Reddy’s Laboratories were worth $6,397,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in shares of Dr. Reddy’s Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after acquiring an additional 1,507 shares during the period. POM Investment Strategies LLC lifted its position in Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after purchasing an additional 1,820 shares during the period. Farther Finance Advisors LLC boosted its holdings in Dr. Reddy’s Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock valued at $40,000 after purchasing an additional 2,093 shares in the last quarter. Independence Bank of Kentucky raised its stake in shares of Dr. Reddy’s Laboratories by 400.0% during the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after buying an additional 2,220 shares in the last quarter. Finally, Allworth Financial LP raised its stake in shares of Dr. Reddy’s Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after buying an additional 2,230 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Stock Performance

RDY opened at $12.37 on Friday. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.36 and a 1-year high of $16.89. The stock has a market cap of $10.32 billion, a P/E ratio of 19.69 and a beta of 0.48. The stock’s 50 day simple moving average is $13.33 and its 200 day simple moving average is $14.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on RDY. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.